Dr. Jatin Kothari Nephrologist in Mumbai

Dr. Jatin Kothari

Nephrologist, Mumbai

MBBS, MD (Medicine), DM (Nephrology)

  • 1 Hospital

About


Specialities

  • Nephrology

  • Transplant surgery

Expertise

Education

  • DM(Nephrology) from Bombay University
  • MD(Medicine) from Bombay University
  • MBBS from Bombay University
  • Fellow,International Society of Nephrology
  • International Transplant Observership, Massachusetts General Hospital, Boston, USA,2009
  • Roche Preceptorship in Kidney Transplantation,University of Alabama,Birmingham, USA ,2006

Practice Information

Nanavati-Max Super Speciality Hospital, Mumbai

Nanavati-Max Super Speciality Hospital, Mumbai

Dr. Balabhai Nanavati Hospital, S.V. Road, Vile Parle (West), Mumbai, Maharashtra - 400056

Achievements & Contributions

  • Study effects of glycemic control on outcomes in peritoneal dialysis(Toronto peritoneal dialysis registry)
  • Intraperitoneal v/s subcutaneous insulin regimes in peritoneal dialysis (Toronto peritoneal dialysis registry)
  • Lipid control in peritoneal dialysis patients-are we meeting targets? (Toronto peritoneal dialysis registry)
  • study of gaps in metabolic acidosis to unmask metabolic alkalosis
  • prospective study of renal disease in Sjogren’s syndrome
  • comparison of creatinine clearance and serum cystatin as markers for estimation of renal function-study completed
  • clinical outcomes in lupus nephritis(data collection completed)
  • An evaluation of safety and efficacy of rHu Epo in treatment of anemia in patients with chronic kidney disease-A prospective open labeled multicenter study-coinvestigator(completed)
  • A randomized single blinded active drug comparitive parallel group, mulitcenter, multinational therapeutic confirmatory study to evaluate safety and efficacy of aropotin v/s espogen in chronic kidney disease patients-co investigator(completed)
  • A Randomized, Double-Blind, Placebo-Controlled, Four Arm, Parallel-Group, Multicenter, Multinational, Safety And Efficacy Trial of 100 mg, 300 mg and 900 mg of Abetimus Sodium In Systemic Lupus Erythematosus (SLE) Patients with a History of Renal Disease”-Principal investigator-study completed
  • Belatacept Evaluation of Nephroprotection and Efficacy as First- line Immunosuppression Trial (BENEFIT) 008 study-Prinicipal Investigator-study completed
  • A Sequential Adaptive Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects with Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE)- completed at our site
  • Biomarkers of acute kidney injury after cardiac surgery(TRIBE-AKI): A pilot study in collaboration with Yale University-USA– Prinicipal Investigator –Study ongoing.
  • Prospective, Multicentre, Randomised, Double-Blind, Parallel Group Study Comparing the Therapeutic Biosimilarity of Epostim™(GMX) with Eprex® (J & J) when given Intravenously to Patients undergoing Chronic Haemodialysis and on Maintenance Erythropoietin Treatment for Anemia Associated with End-Stage Renal Disease ( ESRD) Prinicipal Investigator - study ongoing
  • Belatacept Evaluation of Nephroprotection and Efficacy as First- line Immunosuppression Trial (BENEFIT) 008 study-extension phase till 5 years-Prinicipal Investigator-study started in april 2010.
  • A phase III, randomized, comparative, open label study of intravenous iron oligosaccharide (MonoFer®) administered by weekly infusions or repeated bolus injections in comparison with oral iron sulphate in subjects with non-dialysis dependent chronic kidney disease subjects with renal-related anaemia- Prinicipal Investigator -Study started in june 2010
  • study of gaps in metabolic acidosis to unmask metabolic alkalosis
  • prospective study of renal disease in Sjogren’s syndrome
  • comparison of creatinine clearance and serum cystatin as markers for estimation of renal function-study completed
  • clinical outcomes in lupus nephritis(data collection completed)
  • An evaluation of safety and efficacy of rHu Epo in treatment of anemia in patients with chronic kidney disease-A prospective open labeled multicenter study-coinvestigator(completed)
  • A randomized single blinded active drug comparitive parallel group, mulitcenter, multinational therapeutic confirmatory study to evaluate safety and efficacy of aropotin v/s espogen in chronic kidney disease patients-co investigator(completed)
  • A Randomized, Double-Blind, Placebo-Controlled, Four Arm, Parallel-Group, Multicenter, Multinational, Safety And Efficacy Trial of 100 mg, 300 mg and 900 mg of Abetimus Sodium In Systemic Lupus Erythematosus (SLE) Patients with a History of Renal Disease”-Principal investigator-study completed
  • Belatacept Evaluation of Nephroprotection and Efficacy as First- line Immunosuppression Trial (BENEFIT) 008 study-Prinicipal Investigator-study completed
  • A Sequential Adaptive Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids in Subjects with Active Proliferative Glomerulonephritis Due to Systemic Lupus Erythematosus (SLE)- completed at our site
  • Biomarkers of acute kidney injury after cardiac surgery(TRIBE-AKI): A pilot study in collaboration with Yale University-USA– Prinicipal Investigator –Study ongoing.
  • Prospective, Multicentre, Randomised, Double-Blind, Parallel Group Study Comparing the Therapeutic Biosimilarity of Epostim™(GMX) with Eprex® (J & J) when given Intravenously to Patients undergoing Chronic Haemodialysis and on Maintenance Erythropoietin Treatment for Anemia Associated with End-Stage Renal Disease ( ESRD) Prinicipal Investigator - study ongoing
  • Belatacept Evaluation of Nephroprotection and Efficacy as First- line Immunosuppression Trial (BENEFIT) 008 study-extension phase till 5 years-Prinicipal Investigator-study started in april 2010.
  • A phase III, randomized, comparative, open label study of intravenous iron oligosaccharide (MonoFer®) administered by weekly infusions or repeated bolus injections in comparison with oral iron sulphate in subjects with non-dialysis dependent chronic kidney disease subjects with renal-related anaemia- Prinicipal Investigator -Study started in june 2010 
  • International Transplant Observership, Massachusetts General Hospital, Boston, USA, 2009
  • Roche Preceptorship Award, 2006 for Visiting Scholarship,University of Alabama, Birmingham, USA
  • International Society of Peritoneal Dialysis ISPD) Scholarship Award for training at The University of Missouri Health Sciences, Columbia, USA
  • International Society of Nephrology (ISN) Scholarship(2000)
  • Post Graduate Clinical Research Scholarship Award (1996)
  • Best Paper Award, Indian Society of Nephrology Conference(West zone chapter, November 1999)
  • First rank in Bombay university, DM (Nephrology)(August 1999) with honors
  • Third rank in All India entrance (DM) examinations for the fellowship courses (among a total of 350 candidates from all over the country), May 1997
  • Second rank in Bombay University, MD exams, July 1996 with distinction honors
  • First rank in Bombay university-Final MBBS examinations, April 1992
  • Patient and technique survival of diabetics on peritoneal dialysis: one-center’s experience and review of the literature. Clinical Nephrology, Vol. 69 – No3/2008(193-200)
  • Clinical outcomes of elderly patients undergoing chronic peritoneal dialysis: experiences from one center and a review of the literature: Int Urol Nephrol DOI 10.1007/s11255-007-9279-6
  • Diltiazem use in tacrolimus-treated renal transplant recipients. J Clin Pharm Ther 2004; 29:425-430
  • Volume expansion and sodium balance in peritoneal dialysis-part 1:recent concepts in pathogenesis Advances in peritoneal dialysis Vol 19 2003,36-43.
  • Volume expansion and sodium balance in peritoneal dialysis-part 2:newer insights in management Advances in peritoneal dialysis Vol 19 2003,44-52
  • Cost benefit analysis and prediction of 24 hour proteinuria from the spot protein-creatinine ratio –Clinical Nephrology, Vol 55-No 6/2001(436-447)
  • Acute renal failure in a renal donor due to primary antiphospholipid syndrome-Case report-American Journal of Nephrology 2001:21:55-57
  • Thrombocytopenia due to valproate in a renal transplant recepient-case report, Sounding board, 3-4Transplant Trends April 1999
  • Diffuse proliferative glomerulonephritis in a case of falciparum malaria; Case report; Journal of Renal Sciences, April 1999
  • 10.Hypokalemic periodic paralysis unmasks underlying Sjogren’syndrome- A case report ,and review of literature-IJEM Vol VII No 2 April 2005,97-99
  • Non diabetic renal disease in diabetes mellitus: a review-IJEM
  • An unusual case oh hypercalcemia with a multifactorial etiology-JPGM
  • Pathogenesis and medical management of renal stone disease-Journal of general medicine
  • International Society of Nephrology (ISN)
  • International Society of Peritoneal Dialysis (ISPD)
  • European Dialysis Transplant Association-European Renal Association (EDTA-ERA)
  • Indian Society of Nephrology
  • Indian Society of Nephrology-West Zone chapter
  • Joint Secretary-Zonal transplant coordination committee (ZTCC)
  • Indian Society of Organ transplantation (ISOT)
  • Association of Medical Consultants-Mumbai (AMC)
  • Peritoneal Dialysis Society of India (PDSI)
  • Infectious Disease Society of India (IDSI)
  • Mumbai Nephrology Group (MNG)
-->